微信公众号

请长按图片识别二维码

模型资源

Design of the hTFRC mouse

The humanized TFRC mouse model is developed by Knockin at the mouse TFRC locus, and expresses a chimeric protein with a human extracellular domain (ECD) and a murine transmembrane and intracellular domain.

The humanized TFRC mouse model was intercrossed with the hSA/FcRn double humanized mouse model to enable translatable PK and biodistribution of compounds targeting TFRC.

hTFRC features

  • Entirely humanized TFRC extracellular domain
  • Physiological regulation and expression pattern of human TFRC
  • Fully functional mouse immune system
  • High expression along BBB to allow combined therapies targeting CNS
  • Versatility of applications: oncology and neurology
  • Available on C57Bl/6N genetic background
  • Human TFRC expression mirrors expression of mouse TFRC on different cell types

    Expression of TFRC (anti-mouse TFRC clone C2, anti-human TFRC clone OKT-9) on TER-119+ cells from freshly isolated bone marrow cells (A), blood (B), and splenocytes (C), gated on single viable cells.

     
  • Human transferrin internalization is efficient in cells from hTFRC mice

    Splenocytes of hTFRC mice were incubated with human conjugate pHrodo red transferrin for 2 hours at 37°C. Internalization of human transferrin (Tf) was confirmed by the increase of the MFI values of pHrodo Tf.

    Specific activity of hTFRC: pre-incubation of splenocytes with pHrodo competitor, rh-transferrin, reduced the level of pHrodo internalization.

     
  • Targeting human TFRC improves shuttling to the brain of the anti-BACE1 antibody 

    Combination of anti-hTFRC/anti-BACE1, but not anti-BACE1 alone, enables the biodistribution of IgG in the brain and the reduction of amyloid-β.

    Rational: anti-BACE1 inhibits amyloid-b(Ab) production in vivo (Atwal et al.,2011)

    hTFRC mice were treated with different anti-BACE1/anti-TFRC antibodies for 24h. Concentrations of hIgG and Ab were quantified by ELISA-based assay in plasma and brain homogenates.

None